Both authors are affiliated with the Maryland Center for Multiple Sclerosis at the University of Maryland in Baltimore, MD: Kathleen Costello is the clinical coordinator and Kathleen Conway is the research coordinator and manager.
Nursing Management of MS Patients Receiving Interferon Beta-1b Therapy
Article first published online: 10 JUL 2012
1997 Association of Rehabilitation Nurses
Volume 22, Issue 2, pages 62–81, March-April 1997
How to Cite
Costello, K. and Conway, K. (1997), Nursing Management of MS Patients Receiving Interferon Beta-1b Therapy. Rehabilitation Nursing, 22: 62–81. doi: 10.1002/j.2048-7940.1997.tb01735.x
- Issue published online: 10 JUL 2012
- Article first published online: 10 JUL 2012
In 1993, recombinant interferon beta-1b (Betaseron®, Berlex Laboratories) was approved by the Food and Drug Administration as a treatment for relapsing-remitting multiple sclerosis (MS). Betaseron® is the first therapeutic agent licensed for use with patients with MS in more than 20 years. Many patients and their families have expressed great interest in obtaining information about this agent. In response, MS centers throughout the United States have developed Betaseron® training programs. This article describes how rehabilitation nurses can educate patients and families about Betaseron®.